Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in ...

The company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.

Completing the $7.2 billion buyout of AspenTech "marks a key milestone in the final phase of Emerson's portfolio ...

Landmark exclusive option and license deal with Takeda for ACI-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon ...

A statue of a football hero and a tramway set to transform a town which once won "grumpiest town" in the West Midlands and ...

The completed campus near Salt Lake City will have more than 1 million sq ft of data centers with a combined 175-MW capacity.

Burnaby Hospital’s brand new pavilion will open this year, according to a Burnaby Hospital redevelopment project delegation ...

The Company is planning to announce interim data from its ongoing Halneuron ® Phase 2b chemotherapy induced neuropathic pain ("CINP”) trial in Q4 2025 ATLANTA, March 13, 2025 (GLOBE NEWSWIRE) -- ...

Amid a broad-market correction, digital asset investors have turned to tokenized U.S. Treasury products, pushing their ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash ...